Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
Stopped The study was terminated early due to enrollment difficulties and the futility of observing differences in remission rate between treatment arms.
Conditions
- Pediatric Acute Myelogenous Leukemia (AML)
Interventions
- DRUG: Decitabine
- DRUG: Decitabine
Sponsor
Eisai Inc.